Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATFORM study of genotype-guided precision medicine for rare tumors in China
ChiCTR2000039310Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of almonertinib, dacomitinib, alectinib, crizotinib, vemurafenib and 6 more in Not applicable (see rationale) (13 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate assessed by BICR. Started Oct 2020; status: recruiting.
02
Drugs
almonertinibdacomitinibalectinibcrizotinibvemurafenib
03
Conditions
Not applicable (see rationale)
Beyond the preview
Go deeper on ChiCTR2000039310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039310.